日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non-Small Cell Lung Carcinomas

STK11突变型非小细胞肺癌的综合突变和组织病理学分析

Pineda, Cristiana M; Guan, Zoe; Kwon, Hyunwoo; Rangachari, Deepa; Costa, Daniel B; VanderLaan, Paul A

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

EGFR酪氨酸激酶抑制剂对EGFR 19号外显子插入的非小细胞肺癌患者的疗效:通过LC-SCRUM-Asia(多机构基因组筛查登记)进行的临床基因组学和临床前分析

Uehara, Yuji; Izumi, Hiroki; Kobayashi, Ikei S; Matsumoto, Shingo; Hosomi, Yukio; Okuno, Takae; Sugisaka, Jun; Takase, Naoto; Taima, Kageaki; Sasaki, Shinichi; Teranishi, Shuhei; Miyamoto, Shingo; Mori, Masahide; Nakashima, Chiho; Asano, Shuichi; Oi, Hajime; Sakai, Tetsuya; Shibata, Yuji; Udagawa, Hibiki; Sugiyama, Eri; Nosaki, Kaname; Umemura, Shigeki; Zenke, Yoshitaka; Yoh, Kiyotaka; Ikeda, Sadakatsu; Costa, Daniel B; Kobayashi, Susumu S; Goto, Koichi

Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining results

肺癌中HER2表达模式及其基因组相关性,重点关注影响免疫组化染色结果的分析前变量

Pineda, Cristiana M; O'Loughlin, Lauren; Benjamin, Heather L; Rangachari, Deepa; Viray, Hollis; Widick, Page C; Guan, Zoe; Beattie, Jason A; Swenson, Kai E; Parikh, Mihir S; Majid, Adnan; Costa, Daniel B; VanderLaan, Paul A

How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020s

如何选择奥希替尼或阿法替尼治疗P环和αC螺旋压缩型(G719X、S768I)或经典型(L861Q)EGFR突变:2020年代初期的临床前模型和临床数据告诉我们什么

Berg, Julia M; Kobayashi, Toshiki A; Costa, Daniel B

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

一项关于EGFR突变肺癌患者特征和临床结局的真实世界研究:一线奥希替尼治疗的疗效分析:将FLAURA试验结果推广至常规临床实践

Viray, Hollis; Piper-Vallillo, Andrew J; Widick, Page; Academia, Emmeline; Shea, Meghan; Rangachari, Deepa; VanderLaan, Paul A; Kobayashi, Susumu S; Costa, Daniel B

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer

靶向耐药持续细胞是克服非小细胞肺癌耐药性的一种方法

Izumi, Motohiro; Costa, Daniel B; Kobayashi, Susumu S

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

更正:EGFR酪氨酸激酶抑制剂用于治疗携带罕见EGFR突变的转移性非小细胞肺癌:播客

Le, Xiuning; Nadler, Eric; Costa, Daniel B; Heymach, John Victor

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors

EGFR-T790M 或 EGFR-C797S 介导的靶向耐药性对 EGFR 20 号外显子插入突变活性酪氨酸激酶抑制剂的影响

Kobayashi, Ikei S; Shaffer, William; Viray, Hollis; Rangachari, Deepa; VanderLaan, Paul A; Kobayashi, Susumu S; Costa, Daniel B

Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology-proven malignant pleural effusions

对伴有和不伴有细胞学证实的恶性胸腔积液的肺腺癌进行比较基因组学和免疫病理学分析

Pineda, Cristiana M; Majid, Adnan; Costa, Daniel B; VanderLaan, Paul A

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

EGFR 19号外显子插入突变 EGFR-K745_E746insIPVAIK 及其他罕见的 XPVAIK 氨基酸插入突变:所有已批准的 EGFR 激酶抑制剂类别的有利治疗窗口的临床前和临床特征

Shaffer, William; Kobayashi, Ikei S; Sentana-Lledo, Daniel; Sundararaman, Shriram; Lee, Meghan D; Rangachari, Deepa; VanderLaan, Paul A; Kobayashi, Susumu S; Costa, Daniel B